Globus Medical (NYSE:GMED) Stock Moved Down to Market Perform by BMO Capital Markets

BMO Capital Markets downgraded shares of Globus Medical (NYSE:GMED) from an outperform rating to a market perform rating in a report released on Friday morning, MarketBeat.com reports. They currently have $78.00 price objective on the medical device company’s stock, down from their prior price objective of $94.00.

Several other equities analysts have also recently weighed in on GMED. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a research note on Friday, September 18th. Wells Fargo & Company dropped their price objective on shares of Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a report on Friday, August 7th. UBS Group initiated coverage on shares of Globus Medical in a report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price objective for the company. Finally, Royal Bank Of Canada cut their price objective on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research report on Thursday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $96.92.

Globus Medical Price Performance

Shares of NYSE:GMED traded down $10.77 during trading on Friday, hitting $70.67. 9,272,194 shares of the company’s stock were exchanged, compared to its average volume of 1,321,886. Globus Medical has a 52-week low of $70.39 and a 52-week high of $101.40. The business’s 50-day simple moving average is $77.20 and its 200 day simple moving average is $83.18. The company has a market cap of $9.49 billion, a price-to-earnings ratio of 17.36, a PEG ratio of 1.28 and a beta of 0.98.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The company had revenue of $763.72 million for the quarter, compared to analysts’ expectations of $792.39 million. During the same period in the previous year, the firm earned $1.18 EPS. The firm’s revenue was down .7% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, sell-side analysts anticipate that Globus Medical will post 4.99 EPS for the current fiscal year.

Insider Buying and Selling

In other Globus Medical news, Director Ann D. Rhoads sold 5,000 shares of the stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the transaction, the director owned 35,384 shares in the company, valued at $3,007,640. This trade represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Stephen T. Zarrilli sold 25,000 shares of Globus Medical stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the transaction, the director directly owned 25,000 shares of the company’s stock, valued at $2,176,000. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 60,000 shares of company stock worth $4,838,400. Insiders own 18.38% of the company’s stock.

Institutional Trading of Globus Medical

Large investors have recently made changes to their positions in the business. William Blair Investment Management LLC increased its stake in Globus Medical by 12.6% during the third quarter. William Blair Investment Management LLC now owns 1,447,365 shares of the medical device company’s stock worth $108,408,000 after acquiring an additional 162,469 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Globus Medical by 3.5% in the 3rd quarter. Allworth Financial LP now owns 12,797 shares of the medical device company’s stock valued at $1,011,000 after purchasing an additional 436 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Globus Medical by 335.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 143,614 shares of the medical device company’s stock valued at $10,758,000 after purchasing an additional 110,602 shares during the last quarter. Maryland State Retirement & Pension System boosted its holdings in shares of Globus Medical by 14.7% in the 3rd quarter. Maryland State Retirement & Pension System now owns 6,743 shares of the medical device company’s stock worth $505,000 after purchasing an additional 863 shares during the period. Finally, Jacobi Capital Management LLC purchased a new position in shares of Globus Medical in the 3rd quarter worth approximately $40,000. 95.16% of the stock is currently owned by institutional investors.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.